Trial Profile
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer: A Randomized Controlled Trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Etoposide
- Indications Ovarian cancer
- Focus Therapeutic Use
- 04 Oct 2017 New trial record